LIMN (Liminatus Pharma) Interest Expense: $-0.12 Mil (TTM As of Mar. 2026)


LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $0.16
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Interest Expense?

Liminatus Pharma LIMN +22.63% 13 Interest Expense is $-0.12 Mil as of Mar. 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Liminatus Pharma's interest expense for the three months ended in Mar. 2026 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.12 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Liminatus Pharma's Operating Income for the three months ended in Mar. 2026 was $ -1.10 Mil. Liminatus Pharma's Interest Expense for the three months ended in Mar. 2026 was $ -0.02 Mil. Liminatus Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Liminatus Pharma  (NAS:LIMN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Liminatus Pharma's Interest Expense for the three months ended in Mar. 2026 was $-0.02 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-1.10 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.00 Mil.

Liminatus Pharma's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Liminatus Pharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Liminatus Pharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma Interest Expense Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.22 -0.18 -0.34 -0.22

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.06 -0.02 -0.02 -0.02
LIMN
13GF Score
Liminatus Pharma Inc LIMN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liminatus Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.12 Mil mean?
Liminatus Pharma (LIMN) has a Interest Expense of $-0.12 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Liminatus Pharma and its competitors.
Is Liminatus Pharma's Interest Expense too high?
Liminatus Pharma's current Interest Expense is $-0.12 Mil. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Interest Expense compare to GNPX and PCSA?
Liminatus Pharma's Interest Expense of $-0.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current Interest Expense is $-0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Interest Expense of $-0.12 Mil. The current Interest Expense is $-0.12 Mil. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Interest Expense is $-0.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price